Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Carol P. Y. Lau, Lin Huang, Kwok Chuen Wong & Shekhar Madhukar Kumta. (2013) Comparison of the anti-tumor effects of denosumab and zoledronic acid on the neoplastic stromal cells of giant cell tumor of bone. Connective Tissue Research 54:6, pages 439-449.
Read now
Read now
Hamid Namazi. (2012) Letter to the Editor. Current Medical Research and Opinion 28:11, pages 1755-1755.
Read now
Read now
Articles from other publishers (15)
Nobuyuki Katakami, Takashi Nishimura, Yu Hidaka, Akito Hata, Kazumi Nishino, Masahide Mori, Tomonori Hirashima, Naoto Takase, Toshihiko Kaneda, Hisashi Ohnishi, Satoshi Morita & Yukimasa Hatachi. (2023) Randomized phase II study of zoledronate dosing every four versus eight weeks in patients with bone metastasis from lung cancer (Hanshin Cancer Group0312). Lung Cancer 182, pages 107261.
Crossref
Crossref
Mashari Alzahrani, Carol Stober, Michelle Liu, Arif Awan, Terry L. Ng, Gregory Pond, Bader Alshamsan, Lisa Vandermeer & Mark Clemons. (2022) Symptomatic skeletal-related events in patients receiving longer term bone-modifying agents for bone metastases from breast and castration resistant prostate cancers. Supportive Care in Cancer 30:5, pages 3977-3984.
Crossref
Crossref
. 2022. Arzneimitteltherapie in der Palliativmedizin. Arzneimitteltherapie in der Palliativmedizin
799
885
.
Mashari Alzahrani, Mark Clemons, Marta Sienkiewicz, Noa Shani Shrem, Sharon F. McGee, Lisa Vandermeer, Sandeep Sehdev, Marie France Savard, Arif Awan, Christina Canil, Brian Hutton, Gregory Pond, Deanna Saunders & Terry Ng. (2021) Perceptions around bone-modifying agent use in patients with bone metastases from breast and castration resistant prostate cancer: a patient survey. Supportive Care in Cancer 29:11, pages 6903-6912.
Crossref
Crossref
Terry L. Ng, Megan M. Tu, Mohammed F. K. Ibrahim, Bassam Basulaiman, Sharon F. McGee, Amirrtha Srikanthan, Ricardo Fernandes, Lisa Vandermeer, Carol Stober, Marta Sienkiewicz, Ahwon Jeong, Deanna Saunders, Arif A. Awan, Brian Hutton & Mark J. Clemons. (2020) Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. Supportive Care in Cancer 29:2, pages 925-943.
Crossref
Crossref
Qianyu Wang, Guifang Guo, Zhaohui Ruan, Huijiao Cao, Ying Guo, Long Bai, Chang Jiang, Shousheng Liu, Wenzhuo He, Jinsheng Huang, Yuming Rong, Xuxian Chen, Liangping Xia, Bei Zhang & Roujun Peng. (2020) Safety and Efficacy of Long-Term Zoledronic Acid in Advanced Breast Cancer with Bone Metastasis in South China. Journal of Oncology 2020, pages 1-10.
Crossref
Crossref
Claire Stark Toller, Sarah Charlesworth, Mary Mihalyo, Paul Howard & Andrew Wilcock. (2019) Bisphosphonates. Journal of Pain and Symptom Management 57:5, pages 1018-1030.
Crossref
Crossref
. 2018. Arzneimitteltherapie in der Palliativmedizin. Arzneimitteltherapie in der Palliativmedizin
721
796
.
Agustin Avilès, Maria-Jesùs Nambo, Judith Huerta-Guzmàn, Sergio Cleto & Natividad Neri. (2017) Prolonged Use of Zoledronic Acid (4 Years) Did Not Improve Outcome in Multiple Myeloma Patients. Clinical Lymphoma Myeloma and Leukemia 17:4, pages 207-210.
Crossref
Crossref
. 2015. Arzneimitteltherapie in der Palliativmedizin. Arzneimitteltherapie in der Palliativmedizin
675
747
.
L. Lo Russo, D. Ciavarella, C. Buccelli, O. Di Fede, G. Campisi, L. Lo Muzio, G. Pellegrino & P. Di Lorenzo. (2014) Legal liability in bisphosphonate-related osteonecrosis of the jaw. British Dental Journal 217:6, pages 273-278.
Crossref
Crossref
Nicola Giuliani, Benedetta Dalla Palma & Marina Bolzoni. (2013) Bisphosphonates in Multiple Myeloma: Preclinical and Clinical Data. Clinical Reviews in Bone and Mineral Metabolism 11:3-4, pages 113-121.
Crossref
Crossref
Kent Søe, Torben Plesner, Erik H Jakobsen, Charlotte T Hansen, Henrik B Jørgensen & Jean-Marie Delaissé. (2013) Is retention of zoledronic acid onto bone different in multiple myeloma and breast cancer patients with bone metastasis?. Journal of Bone and Mineral Research 28:8, pages 1738-1750.
Crossref
Crossref
Eduard Vrdoljak, Brian Rini, Manuela Schmidinger, Tomislav Omrčen, Laszlo Torday, Cezary Szczylik & Avishay Sella. (2013) Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone. Anti-Cancer Drugs 24:5, pages 431-440.
Crossref
Crossref
Dino Amadori, Massimo Aglietta, Barbara Alessi, Lorenzo Gianni, Toni Ibrahim, Gabriella Farina, Fernando Gaion, Francesco Bertoldo, Daniele Santini, Roberta Rondena, Paola Bogani & Carla I Ripamonti. (2013) Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. The Lancet Oncology 14:7, pages 663-670.
Crossref
Crossref